Literature DB >> 25483508

Cancer vaccines: what do we need to measure in clinical trials?

Alex Kudrin1.   

Abstract

Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is dedicated to evaluate remaining challenges in capturing clinical response with cancer vaccines. Definition of disease progression in context of clinical rather image-specific criteria and interpretation of efficacy in relation to delayed effect of cancer vaccines should be taken into account in the design of future of immunotherapy trials.

Entities:  

Keywords:  cancer vaccines; endpoints; immune response; patient reported outcomes; progression free survival

Mesh：

Substances：

Year:  2014        PMID： 25483508      PMCID： PMC4514090          DOI： 10.4161/hv.27586

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  8 in total

1.  Kidney cancer: overall survival is an unsuitable primary end point.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba
Journal:  Nat Rev Urol       Date:  2010-07       Impact factor: 14.432

2.  Early accelerated approval for highly targeted cancer drugs.

Authors:  Bruce A Chabner
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  Ovarian cancer treatments on the horizon.

Authors:  Charlie Schmidt
Journal:  J Natl Cancer Inst       Date:  2011-08-17       Impact factor: 13.506

Review 4.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 5.  A clinical development paradigm for cancer vaccines and related biologics.

Authors:  Axel Hoos; Giorgio Parmiani; Kristen Hege; Mario Sznol; Hans Loibner; Alexander Eggermont; Walter Urba; Brent Blumenstein; Natalie Sacks; Ulrich Keilholz; Geoffrey Nichol
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

Review 6.  The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Authors:  Guru Sonpavde; Giuseppe Di Lorenzo; Celestia S Higano; Philip W Kantoff; Ravi Madan; Neal D Shore
Journal:  Eur Urol       Date:  2011-10-24       Impact factor: 20.096

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 8.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506
  8 in total
  2 in total

Review 1.  Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.

Authors:  Ondrej Uher; Veronika Caisova; Per Hansen; Jan Kopecky; Jindrich Chmelar; Zhengping Zhuang; Jan Zenka; Karel Pacak
Journal:  Semin Oncol       Date:  2019-11-06       Impact factor: 4.929

Review 2.  Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

Authors:  Colby S Shemesh; Joy C Hsu; Iraj Hosseini; Ben-Quan Shen; Anand Rotte; Patrick Twomey; Sandhya Girish; Benjamin Wu
Journal:  Mol Ther       Date:  2020-09-30       Impact factor: 11.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.